Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SABBOBCATon May 13, 2021 10:54am
96 Views
Post# 33191363

RE:Got off a call with Leah

RE:Got off a call with Leah

I was not expecting to get through and also not expecting her to take that much time this morning, so I was pleasantly surprised there but also unprepared for a full conversation. I did press regarding the lack of questions and engagement at the AGM and the last quarterly. She acknowledged that for the quarterlies there is the issue of analysts not being able to engage of they are on the webcast vs. dialing in.

 


SABBOBCAT wrote: So I was pleasantly surprised to get through to Leah this morning after the call. Apparently you need to be a registered shareholder (aka shares not held in broker name). So you would have had to get that sorted before the meeting to be able to login, vote, or ask questions. SPCEO, I did let her know thati saw on here you couldnt login, and she said you werent on the registered list.  

 

<< Previous
Bullboard Posts
Next >>